APA

Furfine E. S., Baker C. T., Hale M. R., Reynolds D. J., Salisbury J. A., Searle A. D., Studenberg S. D., Todd D., Tung R. D. & Spaltenstein A. (20040423). Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. : Antimicrobial agents and chemotherapy.

Chicago

Furfine Eric S, Baker Christopher T, Hale Michael R, Reynolds David J, Salisbury Jo A, Searle Andy D, Studenberg Scott D, Todd Dan, Tung Roger D and Spaltenstein Andrew. 20040423. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. : Antimicrobial agents and chemotherapy.

Harvard

Furfine E. S., Baker C. T., Hale M. R., Reynolds D. J., Salisbury J. A., Searle A. D., Studenberg S. D., Todd D., Tung R. D. and Spaltenstein A. (20040423). Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. : Antimicrobial agents and chemotherapy.

MLA

Furfine Eric S, Baker Christopher T, Hale Michael R, Reynolds David J, Salisbury Jo A, Searle Andy D, Studenberg Scott D, Todd Dan, Tung Roger D and Spaltenstein Andrew. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. : Antimicrobial agents and chemotherapy. 20040423.